Last reviewed · How we verify
Sequential therapy 14 days
Sequential therapy 14 days is a treatment regimen combining multiple therapeutic agents administered in a defined sequence over a 14-day period.
At a glance
| Generic name | Sequential therapy 14 days |
|---|---|
| Sponsor | Incheon St.Mary's Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
This appears to be a standardized clinical protocol rather than a single drug entity. Sequential therapy typically involves administering different medications in a planned sequence to optimize therapeutic efficacy and minimize resistance or adverse effects. The 14-day duration suggests a short-term intensive treatment course, commonly used in infectious disease or certain cancer protocols.
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) (PHASE3)
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (NA)
- Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer (PHASE2)
- Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes (PHASE1)
- Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study (PHASE4)
- A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex (PHASE2)
- LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer (PHASE1)
- Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sequential therapy 14 days CI brief — competitive landscape report
- Sequential therapy 14 days updates RSS · CI watch RSS
- Incheon St.Mary's Hospital portfolio CI